MS research 2013
-
Upload
monique-canonico -
Category
Health & Medicine
-
view
140 -
download
13
description
Transcript of MS research 2013
![Page 1: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/1.jpg)
“Courage does not always roar. Sometimes courage is the quiet voice at the end of the day saying, ‘I will try again tomorrow.’ “ ― Mary Anne Radmacher
![Page 2: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/2.jpg)
Monique Canonico DO
Assistant Clinical Professor
University of Hawaii
John A. Burns School of Medicine
RESEARCH UPDATE 2013
![Page 3: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/3.jpg)
OVERVIEW• Update on demographics
• Recent 3 orals approved
• Research updates
• Patient support websites
![Page 4: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/4.jpg)
FACTS ON MS• Now 3:1 female to male
• Those with May birthdays may be more susceptible
• 400,000 people in US have in
• 2 million worldwide
![Page 5: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/5.jpg)
FDA-Approved Disease-Modifying AgentsAubagio (teriflunomide)Avonex (interferon beta-1a)Betaseron (interferon beta-1b)Copaxone (glatiramer acetate)Extavia (interferon beta-1b)Gilenya (fingolimod) Novantrone (mitoxantrone)Rebif (interferon beta-1a)Tecfidera (dimethyl fumarate)Tysabri (natalizumab)
![Page 6: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/6.jpg)
GILENYA• Approved 2011
• Fingolimod is 0.5 mg orally once a day
• Most common side effects headache, flu, diarrhea
• Can cause swelling in eye, low heart rate, increased infections
![Page 7: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/7.jpg)
AUBAGIO• Teriflunimide
• Once daily oral. Category X
• For relapsing remitting
• Blocks the production of overactive T and B cells
• Do not get certain vaccinations on this drug
• Numbness tingling, kidney problems, hair loss
![Page 8: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/8.jpg)
TECFIDERA APPROVED MAR 27• Twice a day
• inhibit immune cells and molecules, and may have anti-oxidant properties that could be protective against damage to the brain and spinal cord
• Titrate up over 1-2 wks.
• Flushing and GI symptoms
![Page 9: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/9.jpg)
WHEN SHOULD A PATIENT SWITCH THERAPIES?
• Neutralizing antibodies
• Adverse reactions
• Progression of disease
• Number of relapses and how well the patient recovers
![Page 10: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/10.jpg)
INTERPRETING THE DRUG DATA• New drugs have been approved recently
• Tecfidera was compared to Copaxone
• Gilenya and laquinimod compared to Avonex
• Aubagio compared to Rebif
• Some clinical and MRI outcomes significantly favored Gilenya over Avonex whereas laquinimod did not show superiority
![Page 11: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/11.jpg)
INTERPRETING THE DRUG DATA(CONT.)• Tecfidera showed a reduction in MRI
activity as compared to Copaxone
• NONE OF THESE DRUGS HOWEVER SHOWED A BENEFIT VS THEIR COMPARATOR ON DISABILITY PROGRESSION
• In most instances the comparator did not reflect the primary outcome of the trial
![Page 12: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/12.jpg)
INTERPRETING THE DRUG DATA(CONT.)
• Best way to compare efficacy is by well designed head to head comparison trials
• These require large numbers of patient and are expensive
• Whether these will occur remains to be seen
• Preliminary evidence from the oral drug trials suggests comparative efficacy; more studies are needed
![Page 13: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/13.jpg)
INTERPRETING THE DRUG DATA(CONT.)• It is still early in the assessment of
safety
• The injectables have been shown to have excellent safety records over long periods of time
![Page 14: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/14.jpg)
Moving on to the latest research….
![Page 15: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/15.jpg)
NEW MS DIAGNOSTIC TOOLS ON HORIZON• Published in Practical Neurology Dec
2012
• “MSPrecise”
• Spinal fluid analysis
• Next generation sequencing assay that evaluates the key genes involved in the immune system of people being evaluated for ms
![Page 16: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/16.jpg)
RETINA’S THICKNESS LINKED TO MS SEVERITY• Dec 12 Practical Neurology
• Measuring the thickness of the retina by OCT (Optical Coherence Tomography
• The retina reflects what is happening in the brain
• May help determine treatment response
![Page 17: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/17.jpg)
PAROXYSMAL DYSARTHRIA AND ATAXIA• Jan 15, 2013 issue of Neurology p. 311
• Initially described by Henry Parker, Irish neurologist, 1946
• Combination associated with MS
• Sudden brief onset of symptoms; could happen many x an hour
• Double vision, tingling, face pain, itching, ataxia
![Page 18: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/18.jpg)
NEW DRUG IN DEVELOPMENT• Published online edition of Neurology
Nov 28,12
• Suvorexant: for insomnia!
• Works on a different brain receptor
• It blocks wakefulness-regulating chemical messengers in the brain called orexins
• Merck is testing it
![Page 19: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/19.jpg)
VACCINES FOR MS TREATMENT• Published in Science of MS Management Apr
2012
• One of the vaccines being tested has genetically engineered DNA that encodes myelin basic protein(a major cytokine target for MS)
• Another strategy for vaccines is t cell vaccination
• Tovaxin is a T cell vaccine based on the individual’s profile based on their t cell response
![Page 20: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/20.jpg)
Your Society at Work !
![Page 21: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/21.jpg)
Apr 17, 2013The National Multiple Sclerosis Society has committed another $18 million to support up to 65 new MS research projects.These new awards are part of a comprehensive Research strategy aimed at stopping MS, restoring function that has been lost, and ending the disease forever.
![Page 22: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/22.jpg)
NMSS FUNDING STUDY ON AXONA• a clinical trial to determine potential
benefits of Accera’s medical food, Axona® (caprylic triglyceride), on cognitive impairment in people with MS
• Axona is an FDA-regulated “medical food”
![Page 23: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/23.jpg)
NMSS FASTFORWARD PROGRAMFUNDS DEVELOPMENT OF DRUG• Spasticity is a common and often painfu
l symptom of MS that involves feelings of stiffness, tightness
• Potential therapy being developed VSN16R
• To help with spasms in all forms of MS including chronic progressive
![Page 24: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/24.jpg)
UK MS SOCIETY FUNDS RESEARCH ON DRUG • This is a study on a drug called
amiloride
• It is a blood pressure medicine
• 14 people enrolled
• Atrophy was reduced
• Larger trial planned
![Page 25: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/25.jpg)
Perseverance is a great element of success. If you only knock long enough and loud enough at the gate, you are sure to wake up somebody.
Henry Wadsworth Longfellow
![Page 26: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/26.jpg)
Large trial in progressive MS: A poster presentation by Dr. David Miller of University College London and an international team suggested that good progress is being made in a large trial of Gilenya® being supported by Novartis. The study involves more than 1000 participants with primary-progressive MS, and it’s designed to determine if Gilenya can slow down MS disability compared to inactive placebo after 3 to 5 years of treatment (Abstract P07.116)
![Page 27: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/27.jpg)
New form of existing therapy for relapsing MS: Dr. Peter Calabresi of Johns Hopkins University presented results of an international, phase 3 trial of peginterferon beta-1a in relapsing MS, a new form of Avonex® designed to stay in the body longer than the standard form. The results over one year suggest peginterferon injected under the skin every two or four weeks was effective in reducing relapse rates and also reduced the risk of progression of disability. This study is continuing into a second year. Trial sponsor Biogen Idec has announced plans to apply for regulatory approval in 2013.
![Page 28: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/28.jpg)
March 2013Copaxone® in fewer doses: Dr. Omar Khan of Wayne State University, Michigan, presented results of a one-year phase 3 trial supported by Teva Pharmaceuticals suggesting that under-the-skin injections of twice the standard dose of Copaxone, taken three times per week, were effective in reducing relapses and MRI-detected disease activity, and revealed no unexpected safety issues.
![Page 29: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/29.jpg)
EXCESS MORTALITY IN MS LARGELY FROM SMOKING• LYON, France Oct 12 -- Much of the early
mortality seen in multiple sclerosis patients is related to their smoking habits, a researcher said here.
• In a prospectively followed cohort of nearly 900 MS patients, 68% of those who died in a 40-year period were current or former smokers, compared with 50% of surviving patients, according to Ali Manouchehrinia of the University of Nottingham in England.
![Page 30: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/30.jpg)
April 2013
Switching therapies: A large study in France called ENIGM tracked the impact of switching from therapy with Tysabri® to Gilenya.® Among 200 people who switched after an average of 30 months on Tysabri, there was a “washout” interval of 3 to 6 months in which no therapy was given and32% experienced a relapse. The researchers concluded that switching increases the likelihood of disease reactivation, and that the washout period should not be longer than 3 months.
![Page 31: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/31.jpg)
EMERGING THERAPIES 2013• Octelizumab-futher testing; treats
relapsing AND progressive
• Laquinamod-elevated liver tests but did decrease progression
• Alemtuzumab-IV drug; FDA evaluating
• Dacluzumab-SQ monthly; decreased MRI and disease progression in preliminary studies
![Page 32: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/32.jpg)
Sugar and progression: a small study from Drs. Wael Richeh, Jesus Lovera and colleagues at Louisiana State University gives food for thought. They asked whether blood sugar is linked to levels of MS disability, and found that people with higher levels of glucose were more likely to have higher levels of disability. This important lead needs more study to prove a role for blood sugar in MS progression.
![Page 33: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/33.jpg)
April 2013Exercise and the brain: A small study from Society-supported scientists Drs. Victoria Leavitt, and others at the Kessler Foundation tested whether aerobic exercise impacts the brain. Using MRI scans and memory tests, they found hints that aerobic exercises (30 minute sessions, 3 times a week, over 3 months) improved memory and increased the volume of the hippocampus, a part of the brain involved with memory and other functions. These preliminary results require additional follow-up.
![Page 34: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/34.jpg)
April 2013Exercise and fatigue: German researchers reported on the impacts of longer-term aerobic exercise to build endurance in people with MS. This study involved 60 people split into two groups: those with fatigue and those without fatigue. Both groups did individualized endurance exercise on treadmills for 12 months. After 6 months of exercise, both groups had improved oxygen consumption, but those who started out with fatigue didn’t show improvement in their fatigue scores until 9 months into the program
![Page 35: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/35.jpg)
CCSVI treatment in MS: First results from a controlled endovascular treatment trial (percutaneous transluminal venous angioplasty) were presented by Drs from State University of New York at Buffalo. In this blinded study, 9 people had the angioplasty and 10 had a sham treatment. At six months, the team did not detect adverse events from the treatment, but also found that it failed to provide sustained improvement in venous outflow. They also found that those whose veins increased In outflow tended to have increased MS disease activity seen on MRI. (Emerging Science Poster P04.273)
![Page 36: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/36.jpg)
APRIL 2013• Lower body weight may increase risk of
PML in those who take Tysabri
• Less than 60 kg
![Page 37: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/37.jpg)
Sep 24, 2012Results of a placebo-controlled, 12-week clinical trial were recently published, showed that Ginkgo biloba failed to improve cognitive function in people with MS. The study involved 121 people with all types of MS whose cognitive tests showed some cognitive impairment. After 12 weeks, no differences were seen between those on Ginkgo and those taking placebo in any of the outcome measures.
Gingko does not improve cognition
![Page 38: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/38.jpg)
Three studies published March 2013 by collaborators at Yale, Harvard and MIT/Broad Institute suggest that dietary salt can speed the development of an MS-like disease in mice, and provide new insights on immune system activity involved in MS.
![Page 39: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/39.jpg)
RESOURCES• nationalmssociety.org
• Mscando.org (lifestyle empowerment)
• Msworld.org (message boards and chat)
• Nfcares.org (supports those who care for their loved ones)
![Page 40: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/40.jpg)
RESOURCES• Assistive Technology Resource Centers
of Hawaii414 Kuwili Street, Suite 104Honolulu, HI 96817(808) 532-7110 (Local)
![Page 41: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/41.jpg)
RESOURCES: ASSISTIVE TECHNOLOGY• Offers a wide variety of assistive
technology (AT) equipment loaned free of charge through centers across the state. Offers customized workshops in AT to meet the specific training needs of university students, professionals, persons with disabilities and their families in Hawaii.
![Page 42: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/42.jpg)
“If you are going through hell, keep going.” ― Winston Churchill
![Page 43: MS research 2013](https://reader034.fdocuments.in/reader034/viewer/2022052601/559093cb1a28abbc538b46d1/html5/thumbnails/43.jpg)